Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation in preclinical models of breast cancer is associated with tumor growth and resistance to anticancer therapies, including paclitaxel. Effects of the pan-Class I PI3K inhibitor buparlisib (BKM120) appear synergistic with paclitaxel in preclinical and clinical models.
Introduction
Taxane-based chemotherapy is an effective first-line treatment option for women with human epidermal growth factor receptor 2-negative (HER2-) locally advanced/metastatic breast cancer [1, 2] . However, over 30% of patients do not respond to first-line treatment, and median time to disease progression is under 1 year [3] . Novel treatment strategies to delay disease progression in this setting are, therefore, required.
The phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is frequently altered in breast cancer, contributing to tumor growth and progression [4, 5] . Besides its role in endocrine resistance, PI3K pathway activation has been implicated in intrinsic and acquired resistance to paclitaxel [6, 7] . Combining paclitaxel with PI3K inhibition represents a potential therapeutic strategy to delay disease progression in patients with advanced breast cancer.
Buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, selectively targets all four isoforms of PI3K (a, b, c, and d), demonstrating antitumor activity in a variety of cell lines and xenograft models with aberrant or wild-type PI3K pathway activity [8] . Buparlisib has demonstrated encouraging signs of clinical activity in patients with advanced solid tumors and breast cancers, either as a single agent [9] or in combination with paclitaxel [10] . We report results of the BELLE-4 phase II/III study (NCT01572727) of efficacy and safety of combined buparlisib and paclitaxel treatment in women with HER2-advanced breast cancer according to PI3K pathway activation status.
Methods Patients
Women aged !18 years with locally advanced/metastatic HER2-breast cancer (confirmed by negative in situ hybridization or immunohistochemistry status 0/1þ) were eligible. Estrogen receptor (ER) and progesterone receptor (PgR) status (positive/negative) was established by local laboratory testing. PI3K pathway activation status was mandatory, determined centrally in archival/fresh biopsy tissue during screening (activation defined by PIK3CA mutation detected by Sanger sequencing in exons 1, 7, 9, or 20 and/or loss of PTEN expression [1þ in 10% of tumor cells] by immunohistochemistry). Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status 1, and adequate bone marrow and organ function.
Patients who had received prior systemic chemotherapy for advanced/ metastatic disease, or prior PI3K/AKT inhibitors, were excluded; prior endocrine therapy was permitted. Other exclusion criteria were local investigator-assessed mood disorders, including history of/active major depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, suicidal attempt/ideation, homicidal ideation, Grade !3 anxiety per Common Terminology Criteria for Adverse Events (CTCAE) v4.03, or other active severe personality disorder. Patients were also ineligible if they had self-assessed depression or anxiety, including scores !12 or positive responses to Question 9 (relating to suicidal ideation) on the 9-item Patient Health Questionnaire, or scores !15 on the 7-item Generalized Anxiety Disorder scale.
Study design
BELLE-4 was a 1:1 randomized, double-blind, placebo-controlled, adaptive phase II/III study. Randomization was stratified by PI3K pathway status (activated/non-activated) and hormone receptor status (positive/negative). Patients received oral buparlisib (100 mg/day) or placebo in combination with intravenous paclitaxel (80 mg/m 2 /week) in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or discontinuation for any other reason. Protocol-defined dose adjustments for buparlisib or placebo were permitted for patients who did not tolerate the dosing schedule. The study was conducted according to the ethical principles of the Declaration of Helsinki.
The primary objective was to determine whether addition of buparlisib to paclitaxel prolonged progression-free survival (PFS) in the full or PI3K pathway-activated population. The key secondary objective was to evaluate overall survival (OS) in populations for which PFS was statistically significant. Overall response rate (ORR), clinical benefit rate (CBR), pharmacokinetics, and safety were also evaluated.
Tumor assessments were conducted locally at baseline, then every 8 weeks after randomization, until disease progression per Response Evaluation Criteria in Solid Tumors v1.1. Safety was monitored throughout the study, with adverse events (AEs) characterized and graded according to CTCAE v4.03.
The study aimed to demonstrate a !50% improvement in median PFS with buparlisib versus placebo, corresponding to hazard ratio (HR) 0.67 in the full and/or PI3K pathway-activated population. The study was conducted in two phases, with a pre-planned interim analysis at the end of the phase II part (at !125 of the targeted 374 PFS events) to determine whether to enroll the full or PI3K pathway-activated population in phase III or stop the study for futility according to pre-specified decision rules (supplementary Figure S1 , available at Annals of Oncology online).
Statistical analysis
Primary PFS endpoints were tested using a log-rank test, stratified according to PI3K pathway activation, and/or hormone receptor status. Assuming a median PFS improvement from 6 to 9 months with buparlisib versus placebo, a total of 374 PFS events were required for final analysis in order to detect HR 0.67 using a log-rank test at a one-sided cumulative 2.5% level of significance. In a traditional phase III study, these assumptions would yield a power of 97.5%. However, considering the adaptive interim analysis and hypothesis-testing strategy in this study [11] , power calculations performed via simulations showed that overall trial power remained >89%. Median PFS, with two-sided 95% confidence intervals (CI), was estimated using the Kaplan-Meier method. The HR for PFS was estimated using a stratified unadjusted Cox proportional hazards regression model, with two-sided 95% CI. ORR and CBR were calculated by treatment group with exact binomial twosided 95% CI.
Results

Patient characteristics and disposition
Between August 2012 and August 2014, 416 patients were randomized to buparlisib and paclitaxel (207; buparlisib arm) or placebo and paclitaxel (209; placebo arm) ( Table 1 , supplementary Figure S2 , available at Annals of Oncology online). In total, 302 (72.6%) patients had hormone receptor-positive (HRþ) disease and 114 (27.4%) had hormone receptor-negative (HR-) disease (i.e. triple-negative breast cancer [TNBC]); 147 (35.3%) patients had PI3K pathway-activated tumors (determined in mainly archival tissue specimens taken at time of initial diagnosis) and 269 (64.7%) had PI3K non-activated tumors. Of those with PI3K pathway-activated tumors, 107 (72.8%) had PIK3CA gene mutations (mainly in exon 9 or 20), 27 (18.4%) had PTEN gene mutations, and 28 (19.0%) had loss of PTEN expression.
Baseline patient characteristics were balanced between treatment arms. In the full population, most patients were Caucasian (72.5 versus 78.5%; buparlisib versus placebo arm), aged <65 years (83.1% versus 78.5%). The majority of patients had visceral disease (72.9% versus 78.0%), and bone metastases (56.5% versus 57.4%). Of note, 23.6% of patients had received no prior treatment (including surgery) at study entry; 48.3% were chemotherapy-naïve; 52.9% were endocrine therapy-naïve. In the PI3K pathway-activated population, a higher proportion of patients in the buparlisib versus placebo arm had bone metastases (69.9% versus 50.0%) and PgR-negative status (42.5% versus 35.1%).
In the full population, the most common reasons for treatment discontinuation were study termination due to futility at interim analysis (29.5% versus 39.7%; buparlisib versus placebo arm), disease progression (28.5% versus 39.2%), and AEs (20.8% versus 7.2%). In addition, more patients discontinued treatment due to physician decisions (mainly related to need/eligibility for new therapy) or patient decisions (mainly related to toxicities) in the buparlisib versus placebo arm (17.9% versus 8.6%). Similar differences were observed between treatment arms in the PI3K pathway-activated population.
Efficacy
At adaptive interim analysis (June 2014), 338 patients had been randomized to treatment. Interim analysis results showed no PFS improvement in the buparlisib versus placebo arm in either the full or PI3K pathway-activated population (Table 2 and Figure  1 ). ORR and CBR were not improved in the buparlisib versus placebo arm (Table 3 ). In the full population, ORR was 22.6% with buparlisib versus 27.1% with placebo. Similar trends were observed in the PI3K pathway-activated and non-activated populations. There was no improvement in CBR in either the full or PI3K pathway-activated population.
The study was terminated due to futility, meeting protocolspecified criteria for futility in both the full and PI3K pathwayactivated population (with predictive powers of 1.8% and 5.2%, both lower than the predefined 35% threshold); phase III was not initiated.
Safety and tolerability
Safety analysis was based on 403 patients randomized at study termination who received at least one dose of study treatment Table 4 ). The most common grade 3/4 AEs (!5% of patients, regardless of study treatment relationship) were neutropenia (14.9% versus 11.4%; buparlisib versus placebo arm), hyperglycemia (8.9% versus 0.5%), rash (7.9% versus 1.0%), increased alanine aminotransferase (6.9% versus 0.5%), fatigue (5.9% versus 3.0%), diarrhea (5.4% versus 2.5%), and alopecia (5.0% versus 2.5%). The most frequent AEs leading to study drug discontinuation were rash (4.5% versus 0%; buparlisib versus placebo arm), fatigue (3.5% versus 2.0%), depression (3.5% versus 0.5%), peripheral neuropathy (3.0% versus 3.5%), and peripheral sensory neuropathy (1.5% versus 4.0%). Of note, psychiatric disorders were responsible for the discontinuation of 7.4% versus 0.5% of patients in the buparlisib and placebo arms, respectively.
Serious AEs (SAEs) were reported more frequently in the buparlisib arm (30.2% of patients) than the placebo arm (20.9%). The most frequent SAEs in the buparlisib arm were pyrexia (3.5%), pneumonitis (3.0%), and diarrhea (2.5%). Seven on-treatment deaths were reported (within 30 days of study drug discontinuation), none suspected to be treatment related. In the buparlisib arm, one patient died due to cardiorespiratory arrest and another due to underlying breast cancer. In the placebo arm, Cox regression model is generated by other strata within study (PI3K pathway activation status-stratified by hormone receptor status; hormone receptor status-stratified by PI3K pathway activation status).
four patients died due to disease progression, and one patient died of cardiac failure.
Discussion
This study investigated whether addition of buparlisib to paclitaxel could prolong PFS in patients with HER2-advanced breast cancer, and whether PI3K pathway activation could predict for treatment benefit with buparlisib. The predefined futility criteria were met in phase II, and phase III was not initiated. There was no clinical benefit from addition of buparlisib to paclitaxel in either the full or PI3K pathway-activated population. Preclinical evidence shows that PI3K inhibition can enhance the efficacy of paclitaxel in combination [7] . However, addition of buparlisib to paclitaxel in patients with PI3K pathway-activated tumors did not provide clinical benefits in this study. Previous studies have also demonstrated lack of efficacy for PI3K-targeting agents in patients with PI3K pathwayactivated tumors [12] , underlining the difficulties in developing effective predictive biomarkers for use in clinical trials and practice. An adaptive phase II/III study design is considered an efficient strategy for the development of targeted treatments where the target patient population is not fully defined [13] . However, PI3K pathway activation status measured in biopsy tissue was not an established predictive biomarker in clinical practice when this study was designed, and was mainly determined in archival tissue specimens that may not have accurately reflected current tumor status [14] . Recent evidence suggests that tumor mutation status can change due to disease progression or exposure to prior treatments [15] . Newer techniques, such as circulating tumor DNA analysis, may help to accurately identify current PI3K pathwayactivated disease and provide more conclusive results [14] .
In this study, median PFS was similar between treatment arms in the full, PI3K pathway-activated, and HRþ population, but tended to be shorter with buparlisib versus placebo in the PI3K non-activated population (HRs were similar in these groups). In the TNBC subgroup, median PFS was considerably shorter with buparlisib than placebo (5.5 versus 9.3 months, respectively), although these results were based on only 37 events. The lack of benefit when adding buparlisib to paclitaxel in this setting may be due to a number of factors. One possible explanation is the higher incidence of discontinuations due to AEs in the buparlisib arm, leading to shorter duration of treatment exposure and reduced paclitaxel exposure than in the placebo arm. In addition, median PFS in the placebo arm (9.2 months) was longer than expected compared with earlier studies (typically 6-8 months), particularly in the TNBC subgroup (typically <6 months) [16] . Several other targeted agents have failed in combination with paclitaxel, underlining its established efficacy as monotherapy in this setting [12, 17] .
Importantly, most patients in this study were relatively treatment-naïve, with almost 25% having received no prior treatment (including surgery) at study entry. The majority of patients had HRþ disease, and only 47.1% of these had received prior hormonal therapy, 17.5% in the metastatic setting. Thus PI3K pathway activation, which is hypothesized to play a role in acquired treatment resistance, may not be an effective therapeutic target in the first-line setting for this disease.
The role of the PI3K pathway in TNBC is also unclear; other molecular drivers appear to play more dominant roles in breast cancer pathogenesis and/or chemoresistance in this patient population [5, 18] . Indeed, efficacy was inferior in the TNBC subgroup compared with other subgroups in this study. It is possible that inclusion of patients with TNBC, who may be less likely to benefit from PI3K pathway-targeted therapy, impacted study results. However, the lack of improved efficacy in the HRþ group suggests the benefit of targeting PI3K pathway inhibition together with chemotherapy may be limited in this first-line setting. In contrast, robust preclinical and clinical evidence demonstrates that the PI3K pathway plays a role in treatment resistance in HRþ disease [19, 20] . This provides a strong rationale for PI3K inhibition in combination with endocrine therapy, and large pivotal studies with buparlisib in this setting are ongoing (BELLE-2 [NCT01610284]; BELLE-3 [NCT01633060]).
The combination of buparlisib and paclitaxel was associated with an AE profile consistent with previous studies of buparlisib-notably hyperglycemia, gastrointestinal and skin toxicities, and mood disorders-and did not impact the decision to terminate the trial at adaptive interim analysis. The most common AEs leading to treatment discontinuation in the buparlisib arm were rash, fatigue, and depression. The greatest difference between treatment arms was observed for rash, which could reflect a potentiation of overlapping toxicities between buparlisib and paclitaxel. While hyperglycemia was a common on-target AE in the buparlisib arm, it rarely led to discontinuations, indicating it was well managed in this study.
In conclusion, the combination of buparlisib and paclitaxel did not improve PFS compared with paclitaxel alone in either the full or PI3K pathway-activated population in this study. As a result, the trial was stopped at the end of phase II due to futility, and phase III was not initiated.
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